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Abstract
This paper reports on the ‘Prader-Willi Syndrome (PWS) Mental Health Research Strategy Workshop’ that took place
in March 2015. PWS is characterized by a complex phenotype affecting multiple systems with a high prevalence of
maladaptive behaviours, and neuropsychiatric illness. Prader Willi syndrome results from the absence of paternally
derived alleles located at the imprinted chromosomal locus, 15q11–13. The goal of the workshop was to highlight
the state of the science of the mental health of people with this rare neurodevelopmental disorder. Mental ill
health and maladaptive behaviors significantly impact quality of life for persons with PWS and their caregivers.
Effective treatments and further research into this area are critically needed.
Methods: A multidisciplinary group of scientists and health care professionals were brought together to discuss the
mental health and behavioral needs of people with PWS. The workshop strategy was to integrate established work
on PWS with other relevant areas of study. The meeting also focused on two neurobiological systems that research
had suggested were relevant to understanding the broader mental health aspects of PWS: the autonomic nervous
system and oxytocin/vasopressin pathways. Other relevant topics were considered and recommendations made.
Results: The workshop presentations and working group discussions revealed that no one approach was sufficient
to fully conceptualize the mental health challenges in PWS. Workshop discussions pointed to the need for
theoretically informed studies focused on clinical characterization, measurement, and the probing of specific
neurobiological systems through pharmaceutical or other interventions. Future studies in this area should explore
the use of advanced neuroimaging protocols, as well as molecular studies using iPS cells in order to create more
informed theories.
Conclusions: Within this framework, workshop participants identified and prioritized key research questions, and
highlighted current opportunities. Recommendations were made with respect to the development of specific
resources and tools for furthering mental health research such as The Global PWS Registry, the development of
effective endpoints, the use of animal models and iPS cells to aid understanding of the neurobiological
underpinnings. Additionally, collaborative opportunities across disciplines and syndromes were highlighted and
targeted research initiatives focused on psychological/behavioral interventions modified for use in PWS were
recommended.
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Background
PWS is a rare, genetically determined neurodevelop-
mental disorder characterized by a complex phenotype
affecting multiple systems with a high prevalence of mal-
adaptive behaviors, including neuropsychiatric illness. As
is the case with many rare neurodevelopmental syn-
dromes of genetic origin, PWS is associated with specific
physical features and a characteristic developmental pro-
file that make up the core diagnostic criteria for the dis-
order. There are also high rates of specific problem
behaviours and psychopathology, which have become
known as the ‘behavioural phenotype’ of the syndrome
[1–3]. The aims of previous research have been to
characterize these problems and to then identify the de-
velopmental, biological, and psychological mechanisms
that directly or indirectly link the genotype to this
phenotype. The central aim of the ‘Prader-Willi Syndrome
(PWS) Mental Health Research Strategy Workshop’, which
was held in 2015, in Bethesda, Maryland, was to review
the state of the science and develop a strategy for moving
the field forward. The workshop included clinicians and
scientists active in mental health research into PWS and/
or other neurodevelopmental syndromes, as well as family
members, some of whom have also been actively engaged
in research. In this paper we report on the proceedings of
the workshop, providing an authoritative overview that
identifies key target areas in need of comprehensive study
and considers potential methodologies for pursuing such
studies. The following sections will provide highlights
from the workshop and will summarize the formal presen-
tations, interactive sessions and final discussion session
outlining workshop recommendations.
Overview of the workshop
At the opening reception Lauren Schwartz, PhD (Uni-
versity of Washington) discussed the behavioural
complexities of people with PWS, and the challenges
in helping them navigate through life. The urgency
and importance of mental health challenges in PWS
was emphasized from a parent and clinician perspec-
tive. Elisabeth Dykens, PhD (Vanderbilt University)
highlighted the breadth of PWS symptoms arguing
that this both required, and should encourage, more
psychiatric investigators to study PWS. She empha-
sized not only the importance for people with PWS
and their families that we better understand these
problems but also the value of PWS as an ideal, but
under-recognized, model for elucidating the biological
underpinnings of psychopathology in the general popula-
tion. A “Work in progress” poster session followed these
presentations. The posters focused on a range of relevant
topic areas including: further characterization of the
behavioural and psychiatric phenotype; learning strengths
and challenges in PWS; behavioral interventions for
anxiety, obsessive compulsive disorders, and aggressive
behaviors in PWS; unique responses seen in individuals
with PWS to psychiatric medications; neuroimaging
studies; and the use of induced pluripotent stem cells
to investigate the molecular basis of psychopathology
in PWS.
The first full day of the workshop began with an over-
view of mental health in PWS followed by presentations
from experts in related fields of mental health and devel-
opmental disability research. The goal of these talks was
to identify how to apply knowledge in related areas
towards new ways of conceptualizing and addressing
mental health in PWS. The Workshop also included two
highly interactive sessions addressing provocative questions
in PWS mental health: “Can We Prevent or Mitigate
Psychosis in PWS?” and what was referred to as “The Oxy-
tocin Conundrum”. Finally, afternoon breakout sessions
focused on the identification of key issues and research pri-
orities within five topic areas, with a final summary and
discussion session for consensus recommendations.
Current state of the science
‘The problem behaviours and psychopathology in PWS’
was presented by Anthony Holland, M.D., (University of
Cambridge). Dr. Holland outlined the current under-
standing of the features of PWS over the lifespan
highlighting changing areas of need with respect to the
eating behavior/hyperphagia, other problem behaviors
and the propensity to mental illness. PWS is a genetic-
ally determined neurodevelopmental disorder associated
with a phenotype that strikingly changes early in the life-
span [2]). Briefly, infants with PWS invariably fail to
thrive and are hypotonic at birth and unable to suckle.
Children are usually slow to develop with evidence later
in childhood of an intellectual impairment and learning
disabilities. Over-eating/hyperphagia also begins to de-
velop in young children with five relatively distinct
phases now described [4]. The hyperphagia is considered
to be due to an impaired satiety response and a high re-
ward value of food for individuals with PWS [5–7]. As
children with PWS develop, characteristic physical fea-
tures of PWS become apparent but these are largely
minimized by growth and sex hormone replacement [8].
Adolescents and adults are particularly at risk for severe
obesity because of the propensity for over-eating and in-
creased opportunities to obtain food in different work or
community settings. The hyperphagia and the relative
growth and sex hormone deficiencies of pituitary origin,
together with irregularities of sleep, temperature regula-
tion and the report of reduced numbers of oxytocin con-
taining cells in the para-ventricular nucleus, highlight
the central role of the hypothalamus in the core aspects
of the PWS phenotype [9].
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The life course of people with PWS is also associated
with a high risk for specific maladaptive behaviours and
neuropsychiatric disorders, which are not unique to
PWS, but are more prevalent than in other neurodeve-
lopmental disorders associated with intellectual disabil-
ities. Rates of psychopathology are high and generally
remain so over time [10]. This PWS ‘behavioural pheno-
type’ includes: a) repetitive and ritualistic behaviours
[11] similar to those found in autistic spectrum condi-
tions [12]; b) temper outbursts that tend to occur at
times of unexpected or unwanted change [13]; c) skin
picking or other forms of self-injury that vary in nature
and intensity [14]; d) mood disorders that can be cyclical
in nature and characterized by both hypomanic and de-
pressive phases [15]; and e) psychotic illness, mainly in
people with PWS due to maternal uniparental disomy
(mUPD) of chromosome 15, which is predominately
affective in nature and may develop as early as the teen-
age years with the occurrence of abnormal mental beliefs
and experiences [15–17].
These behavioural and psychiatric problems are found
across all three of the major PWS genotypes (Type I or
II deletions at 15q11–13, mUPD) with some differences
in intensity or degree of problems across the lifespan
[18, 19]. The most striking difference with respect to the
different genotypes is the very high risk for affective
psychosis seen in adults with PWS mUPD, with approxi-
mately 60 % displaying psychosis that usually presents in
the late teens or early adulthood [16, 17, 20]. In contrast,
psychotic illness is less often found in those with PWS
due to deletion (~20 %), with depression reported in
both genetic subtypes (20–25 %, [20]).
It has been proposed that the increased liability to
non-psychotic mood disorders in PWS may be due to
the absence of the snoRNA, SNORD115 (previously
called HBII-52) and its effect on the serotonin 2C recep-
tor [21, 22]. However, psychotic illness, which is more
common in those with mUPD, may be a consequence of
a second ‘genetic hit’ due to the excess expression of
paternally imprinted gene(s) located on chromosome 15
[15]. In one of the few follow up studies on psychotic
illness in PWS [23], contacted 48 individuals who had
taken part in a previous study and had had episodes of
psychosis at that time or were at increased risk of devel-
oping psychosis due to their genetic subtype. The [23]
study found among the 28 adults who agreed to partici-
pate in the follow up, that recurrent episodes of psych-
osis were relatively uncommon (2 out of 28 participants
had recurrent illness) once stability had been achieved
with psychiatric medication. The medications included
antipsychotic medication, SSRIs and/or mood stabilizers,
used singularly or in combination. While standard psy-
chiatric treatments were used to treat the psychotic
illness with reasonable effect, the question remains
whether from a pathophysiological perspective, the
affective and psychotic illness in PWS should be seen as
similar to or different from similar psychiatric illnesses
in the general population.
The two main genetic subtypes of PWS also differ in
intellectual profiles and level of social functioning. The
deletion group generally having better visuo-spatial
skills, while the mUPD group has higher verbal func-
tioning [24, 25]. Those people with PWS due to mUPD
have more features of autism spectrum disorders [26]
and have also been shown to be slower at cognitive
processing [27]. The molecular mechanism(s) underlying
these differences in phenotype remains to be determined.
In clinical practice the implications of such observations
for direct support staff and clinicians is the recognition of
the potential benefit of specific support strategies and,
where appropriate, ‘autism informed’ interventions to
minimize problem behaviours.
While the PWS behavioural phenotype is now well
recognized it is not yet clear whether there are shared or
separate mechanisms that directly or indirectly link the
PWS genotype to different aspects of the behavioural
phenotype. Factor analysis suggests three groupings of
behaviours: a) eating disorder, lying and stealing; b) re-
petitive and ritualistic behaviours and temper outbursts;
and c) skin picking and mood disorders. Each of these
three groups may have different causal mechanisms [28].
For example, impaired set-shifting ability and different
patterns of brain activation have been shown to be asso-
ciated with increased temper outbursts, when routines
are disrupted, and with repetitive and ritualistic behaviours
[13, 29, 30]. Interestingly, the notion that environmental
predictability is an important part of the management of
such behaviours has been challenged, proposing instead
that such adherence to routine may lead to more severe
outbursts when those routines are then subsequently
broken [31].
The key message of these examples of more recent
research is that identifying possible neural and psycho-
logical mechanisms linking genotype to the PWS behav-
ioural phenotype allows for more targeted and effective
treatments. While structured and behavioural observa-
tions over time are critical, understanding the basis for
such observations is clearly enhanced by combining with
advanced neuroimaging. Studies to elucidate the behav-
ioural and mental health needs of people with PWS can
also take other forms including the use of specific inter-
ventions aimed at ‘probing’ particular neurotransmitter
systems. An example of this can be seen in the open label
study of N-acetylcysteine, a modulator of the excitatory
glutaminergic pathway, in which Miller and Angulo [32])
reported reductions in the extent and severity of skin pick-
ing. Other emerging areas of therapeutic investigation that
are redirecting attention to different explanations for such
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behaviours include oxytocin for social impairments and
anxiety (see below), vagus nerve stimulation for behav-
ioural difficulties [33], behavioural interventions including
mindfulness and cognitive behavior therapy, and detailed
functional analyses such as been undertaken with skin
picking [14].
From a clinical perspective the state-of-the-art remains
that of a detailed assessment that brings together per-
spectives of applied behavioural analysis and the identifi-
cation of physical and psychiatric co-morbidities. This
assessment also must focus on identifying the interplay
of developmental behaviours, acquired co-morbid illness,
and/or other disturbances (e.g. sleep disorders) with fac-
tors in the environment that might predispose, precipitate
and maintain the problematic behaviours or abnormal
mental state (see best practice guidance, [34]).
Lessons from other neurodevelopmental disorders and
specific neurobiological systems
Tony Simon, PhD (University of California, Davis), pre-
sented “Cognitive-affective interactions and psychosis risk
(and Protection?): The case of 22q11.2 deletion syn-
drome”. This particular syndrome was chosen as PWS
and 22q deletion share many features, including develop-
mental delay, increased anxiety, and high risk of psychotic
illness. Dr. Simon explained that individuals with 22q
deletion can be separated into two groups based on their
level of anxiety– those who manage anxiety well, termed
“copers”, and those battling their anxiety, termed “strug-
glers”. This distinction between coper and struggler is in-
dependent of IQ, and instead correlates with allostatic
load, or repeated and chronic stress [35]. Copers do better
than strugglers in real world functioning and may outper-
form expectations based on cognitive testing alone, while
the opposite is true for strugglers. “Strugglers” appear to
be at greater risk for mental illness as allostatic load is also
correlated with psychiatric difficulties in many populations
([35, 36]. Given these findings the importance of creating
environments to help children become “copers” by speak-
ing to children’s strengths and decreasing allostatic load/
stress levels was clearly apparent. One approach is match-
ing the person’s abilities to the demands of a particular
situation or task. This may be accomplished with a variety
of tools and approaches –employing behavioral therapy,
creating an appropriate and supportive educational envir-
onment, using medication as needed, and setting realistic
expectations for families and schools. A key question is
whether the anxiety/coper/struggler paradigm also applies
to our understanding of people with PWS.
Stephen Porges, PhD (University of North Carolina)
spoke on “The polyvagal theory and autonomic nervous
system function: implications for the understanding of
the behavioural phenotype of PWS”. This topic had been
selected as results from a small study on the use of
vagus nerve stimulation in people with PWS had found
significant improvements in behavior (Manning [33]).
The polyvagal theory [37] is focused on the flight, fight
or freeze responses to a real or imagined threat, and the
impacts on social behavior and psychological function-
ing. Previous research drawing on the polyvagal theory
has provided insights into the mechanisms mediating
symptoms observed in several behavioral, psychiatric,
and physical disorders as well as in autism [37–39].
Porges proposes that defects in the vagus system specif-
ically in the “vagal break” may be related to deficits in
social communication seen in PWS. These proposed de-
fects may also underlie or trigger anxiety and temper
outbursts. Future research is needed to determine how
this model may highlight mechanisms in PWS that are
disrupted and point towards novel treatment approaches
for mental health challenges. The results from the Manning
et al. [33]) pilot study indicate that the thresholds for when
these behaviours are triggered by environmental events
may possibly be moderated through manipulation of the
vagus nerve as part of the autonomic nervous system. Fur-
ther research into this pathway in PWS is warranted.
The final keynote presentation focused on the im-
portance of measurement in clinical trials drawing upon
work in Fragile-X syndrome (FXS) conducted by
Elizabeth Berry-Kravis, MD, PhD (Rush University Med-
ical Center) and colleagues [40, 41]. Dr. Berry-Kravis
presented “Outcome measures for treatment trials in fra-
gile X syndrome: hurdles, lessons and progress”. During
this presentation, Dr. Berry-Kravis reviewed information
from her previously published paper [40] on measuring
endpoints and outcomes in clinical trials for Fragile X.
Dr. Berry-Kravis detailed what has and has not worked
for the FXS clinical studies [40, 41] and outlined ideas
regarding ways the PWS research community could suc-
cessfully adapt and develop effective measures to be
used in PWS treatment studies. Several concepts were
emphasized including taking the time to develop ap-
propriate endpoint measures and the need for intense
collaboration among researchers, clinical teams and
caregivers. Global registries were identified as excellent
resources to collect data to inform such endpoint devel-
opment particularly for rare diseases.
Interactive sessions
The first interactive session entitled “Can we prevent or
mitigate psychosis in PWS?” focused on whether a clin-
ical trial is warranted targeted at preventing the onset or
recurrence of psychosis in PWS. The session was moder-
ated by Anthony Holland, MD who summarized what is
known about the onset of psychosis in PWS. Questions
were then put to the group, is a clinical trial warranted?
If so, what should the intervention be? What ethical
issues need to be addressed? How would such a trial be
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conducted? After a thoughtful discussion, a general
consensus was reached that better identification and
characterization of persons with PWS who are at most
risk is needed prior to a trial. There was strong con-
sensus that current efforts should focus on better identi-
fying those subgroups and on characterizing the
“prodromal” symptoms of psychiatric illness in PWS. Fi-
nally, determining the underlying biological mechanism
of psychosis would help in designing an optimal clinical
trial. Various ways of approaching such studies were
discussed as well as various intervention modalities in-
cluding psychiatric medication, omega-fatty acids [42]
and cognitive therapy [43].
“The Oxytocin Conundrum” Long time expert in the
area of oxytocin research, Sue Carter, PhD (Indiana Uni-
versity) presented an overview of the research on the
biology of oxytocin. The usefulness of intra-nasal oxyto-
cin in PWS remains uncertain as findings from initial
clinical trials exploring the use of oxytocin in PWS are
mixed [44], found positive effects of intra-nasal oxytocin
on social functioning and behavior in PWS. However, no
differences were found in a double blind placebo con-
trolled trial [45], with worsening of temper outbursts
found at the highest dose of oxytocin. Despite these
seemingly conflicting results, there remained interest
among the PWS researchers to continue to explore the
potential utility of this medication for PWS. Group dis-
cussion focused on possible new ways of understanding
how the oxytocin and vasopressin systems may be dis-
rupted in PWS. Workshop participants identified key is-
sues to address in future research including examining
deficits in long acting and intermediate forms of oxyto-
cin and the resultant effects on vasopressin receptors, as
well as identifying critical windows for oxytocin action
in the developing brain. Additionally, dosing issues were
recognized as likely to be crucial for a positive effect and
the timing of that dosing will likely vary across age
groups of persons with PWS. Finally, Dr. Carter empha-
sized that in general lower doses of oxytocin at critical
windows may be more beneficial than higher doses [46].
Identification of Key issues
During the second part of the meeting, Workshop par-
ticipants were each assigned to moderated working
groups. The working group discussion topics focused on
a series of pressing mental health challenges in PWS.
These mental health areas of most pressing need were
identified before the workshop via a survey completed by
researchers and parents/caregivers. The top five topics
identified via this survey were: 1) depression/mood issues,
2) Anxiety/Obsessive Compulsive behaviours, 3) Temper
outbursts, 4) Social challenges and 5) further developing
the Research Infrastructure for PWS mental health re-
search. The moderators of each of the groups synthesized
the discussion into a brief summary for final presentation
and discussion with the full group. Table 1 summarizes the
top 10 consensus recommendations from the working
groups. These can be divided broadly into three areas: 1)
the development of the necessary resources and research
tools/strategies to enable the research – this was as broad
as the use of the Global PWS registry to better understand
the natural history of mental health and behavior in PWS,
the development of outcome measures to support clinical
studies and trials, and the use of animal models or iPS
cells derived from people with PWS to better under-
stand the neurobiological underpinnings of these dis-
orders; 2) the advancement of theories and the
research strategies directed towards testing such the-
ories, with a particular focus on the oxytocin/vaso-
pressin and autonomic nervous systems; and 3) the
undertaking of clinical trials of psychological and
other interventions both to inform clinical practice and
also as a means of better understanding etiology.
Conclusion
Individuals with PWS represent a genetically defined
population with a high incidence of maladaptive behav-
iours and increased susceptibility to psychiatric illness.
Table 1 Top 10 research priorities from the PWS Mental Health
Workshop
1. Obtain longitudinal and natural history data on mental health in
PWS, including the behavioral and psychiatric components of the
PWS phenotype. The Global PWS Registry will be a critical resource to
advance mental health research since it will compile data on mental
health over the lifespan.
2. Develop effective outcome measures for PWS mental health
treatment studies, fully utilizing the Global PWS Registry to facilitate
the development of such tools.
3. Determine the influence of weight management, hormones, and
environment on mental well being over the life course, using
validated measures of well-being.
4. Apply diverse research methods to advance mechanistic research on the
neurobiology underlying mental health and behavioral issues in PWS.
5. Identify markers (neurobiological, genetic, psychological,
environmental) of impending mental illness and characterize features
of the prodromal phase (especially psychosis) in PWS, to allow
mitigation and/or prevention of psychiatric episodes through
environmental, behavioral or pharmacological interventions; and
evaluate effectiveness of such interventions.
6. Facilitate further research on oxytocin and vasopressin in PWS in
order to refine the timing and dosing of future oxytocin trials in PWS.
7. Further assess autonomic nervous system function in PWS to
determine if the polyvagal theory and treatments help explain or
ameliorate temper outbursts, anxiety and other behavioral problems.
8. Adapt or modify current state of the art behavioral interventions,
including mindfulness, for anxiety, obsessive compulsive behaviors,
and temper outbursts for PWS, and test their effectiveness over time.
9. Develop accessible methods and approaches to help reduce high
levels of parental/caregiver stress, and determine effects of reducing
caregiver distress/stress on child functioning.
10. Involve parents, families and caregivers (both family and
professional) at all levels; Workshop attendees felt that their vast
experience and engagement will be critical to advancing knowledge
and treatment, with input as well from youth and adults with PWS.
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Understanding the basis of the phenotype in this rare dis-
order is likely to provide insight into more common forms
of mental health concerns in the general population. It is
hoped that this PWS Mental Health Research Workshop
Summary will give researchers and clinicians a framework
for understanding some of the key mental health chal-
lenges in PWS and the state of current research. Further,
workshop recommendations can guide funding agencies
in prioritizing future mental health research initiatives,
thereby streamlining resources. Strengthening collabor-
ation among the outstanding investigators at the meeting
as well as additional experts in the field and advocates will
be critical to advancing this research agenda.
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